Haven't used OncoResponse yet?
Ask AI

Ask AI about OncoResponse

Generated with AI from 12 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

Robert Friel
Reviews 1

I had a very satisfactory experience with OncoResponse. They provided excellent service and their website was easy to navigate. The information on their website was very helpful and informative. I would highly recommend OncoResponse to anyone in need of their services.

Ian Austin
Reviews 1

I recently used the services of a company and I am very satisfied with their service. The website was easy to use and provided all the information I needed. The staff was knowledgeable and answered all my questions. I highly recommend their services.

Saradha Mp
Reviews 1

I recently used the services of this company and I have to say that I'm very impressed. The website was user-friendly and the information provided was comprehensive. The staff was also very helpful and responsive. I highly recommend their services.

Questions & Answers

No questions yet — be the first to ask.

News & Press

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying widget on your website — its a simple way to convert your visitors into customers.

Embed code

<script src="https://trustburn.com/widgets/index.js"></script>
<div class="trustburn-widget" data-trustburn-protocol="https:" data-trustburn-domain="trustburn.com" data-trustburn-widget="score" data-company-path="oncoresponseinc-com" data-lang="en"></div>
More widgets

About OncoResponse

OncoResponse Inc., an immuno-oncology company located in Houston, Texas, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to cancer therapeutic monoclonal antibody and target discovery. The company licensed the I-STAR™ platform, developed and validated by Theraclone Sciences of Seattle, to interrogate the human memory B-cell repertoire of cancer patients who are considered “Elite Responders” to immunotherapy; as such, their own adaptive immune system responded to immunotherapy stimulation in a way that achieved curative or durable responses. From these Elite Responders, OncoResponse is leveraging the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of fully human antibody derived therapeutics for the treatment of cancer.